Home/Iovance Biotherapeutics/Jean-Marc Bellemin
JB

Jean-Marc Bellemin

Chief Medical Officer

Iovance Biotherapeutics

Therapeutic Areas

Iovance Biotherapeutics Pipeline

DrugIndicationPhase
Amtagvi (lifileucel)Advanced Melanoma (post-anti-PD1)Approved
LifileucelAdvanced Non-Small Cell Lung Cancer (NSCLC)Phase 2
TIL + PembrolizumabAdvanced Front-line MelanomaPhase 3